semaglutide vs placebo Kidney and Survival Benefits of in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses In a phase 3a study

Poisons Standard

Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, OFarrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept

Mean baseline BMI was approximately 40 kg/m

British Journal of Clinical Pharmacology, 35 , 409412

Continue to monitor your weight and health with your provider

Despite clear microbial shifts correlating with disease severity, these patients had lower plasma TMAO levels than asymptomatic controls, suggesting a complex interplay between gut microbiota composition and metabolic risk pathways